News & Events
LOCUS PHARMACEUTICALS ENTERS INTO RESEARCH COLLABORATION
BLUE BELL, PA - October 9, 2009 - Locus Pharmaceuticals announced today that it has entered into a discovery research collaboration with Novartis. Locus will collaborate with Novartis to discover novel chemotypes on targets of interest to Novartis' select therapeutic areas.
"We are very excited about the opportunity to work with such a prominent pharmaceutical company to enhance their drug discovery efforts using the Locus technology," said Dr. Joan Lau, President of Locus Pharmaceuticals. "The strength of the Locus discovery process lies not just with the technology, but also the integrated drug design team approach, uniquely customized for each project," she added.
About Locus Technology
Locus has developed and successfully applied a novel virtual fragment-based drug design (FBDD) platform into an integrated system for drug discovery. Driven by computational protein modeling and FBDD technology, Locus' technology supports rapid discovery of novel target-selective drug molecules. The technology platform is broadly applicable to many target classes including, but not limited to kinases, proteases, and receptors. Drug design teams comprised of experienced computational and medicinal chemists are trained to utilize the suite of Locus computational tools.
About Locus Pharmaceuticals
Locus Pharmaceuticals, Inc. is a privately held drug discovery and development biotechnology company in Blue Bell, PA creating novel therapeutics using its patented drug design technology. Locus has entered into several drug discovery collaboration projects with pharmaceutical partners, and built a pipeline of early drug development assets for cancer and inflammatory indications. Locus transformed its business model in 2008 to provide a unique drug discovery platform for pharmaceutical partners using its computational and medicinal chemistry resources and technology.